Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer

Liang Zeng,1,2,* Yizhi Li,2,* Qinqin Xu,3,* Wenjuan Jiang,2 Analyn Lizaso,4 Xinru Mao,4 Yongchang Zhang,2 Nong Yang,2 Zhenxing Wang1 1Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, People’s Republic of China; 2Department of Medical Oncol...

Full description

Bibliographic Details
Main Authors: Zeng L, Li Y, Xu Q, Jiang W, Lizaso A, Mao X, Zhang Y, Yang N, Wang Z
Format: Article
Language:English
Published: Dove Medical Press 2020-07-01
Series:OncoTargets and Therapy
Subjects:
alk status evaluation
alk ihc
alk inhibitor
Online Access:https://www.dovepress.com/comparison-of-next-generation-sequencing-and-ventana-immunohistochemis-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/comparison-of-next-generation-sequencing-and-ventana-immunohistochemis-peer-reviewed-article-OTT

Similar Items